ArticleFrontiers in molecular biosciences2025
CSDE1 stabilizes AGO2 in embryonic stem cells.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cold shock domain (CSD)-containing protein, CSDE1, interacts with AGO2 and regulates miRNA function in post-transcriptional gene silencing. While the individual roles of CSDE1 and AGO2 in regulating gene expression underlying stem cell pluripotency and differentiation are well known, the effects of their interaction remain unclear. Here, we demonstrate that CSDE1 stabilizes AGO2 and key pluripotent proteins, NANOG, SOX2, and Oct4, in mouse embryonic stem cells. CSDE1 stabilizes AGO2 and the stem cell markers, preventing their ubiquitination. Further, the N-terminal domain, CSD1, which is necessary for CSDE1 interaction with AGO2, is crucial for maintaining AGO2 levels and the pluripotent proteins, thereby revealing an additional layer of control over AGO2 function and gene expression associated with stem cell fate at the post-translational level.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.